Watch this video to understand the mode of action of Chimeric Degradation Activating Compounds (CDAC), a new investigational targeted approach for hematologic malignancies.
Video
View this interactive infographic to learn more about acquired BTK mutations that can result in drug resistance.
Reading
Zanubrutinib is a next-generation Bruton’s tyrosine kinase inhibitor (BTKi) designed for selectivity, potency, and bioavailability. Watch the mode of action (MoA) video to learn more.
Video
Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind and inhibit PD‑1. Watch the mode of action (MoA) video to learn more.
Video
